Infectious mononucleosis is a more realistic target for preventing multiple sclerosis
Multiple Sclerosis and Related Disorders,
Год журнала:
2025,
Номер
95, С. 106337 - 106337
Опубликована: Фев. 18, 2025
Язык: Английский
The use of peptides for deciphering the mechanism of EBV, HPV, and HCV invasion of human cells
Опубликована: Март 26, 2025
Epstein-Barr
virus
(EBV),
human
papillomavirus
(HPV),
and
hepatitis
C
(HCV)
are
significant
pathogens
associated
with
various
diseases,
employing
complex
molecular
mechanisms
for
cellular
entry
immune
evasion.
Peptide-based
research,
using
more
than
700
synthetic
peptides,
has
deciphered
some
of
the
interactions
between
viral
proteins
host
cell
receptors,
offering
promising
diagnostics
therapeutic
strategies.
In
EBV,
binding
peptides
have
been
identified:
11382,
11389,
11416
derived
from
gp350/220;
11435,
11436,
11438
gp85
[glycoprotein
H
(gH)];
11521
BNRF1/p140.
Most
these
peptide
sequences
surface-exposed
part
contact
regions
making
them
candidates
strategies
aimed
at
inhibiting
EBV
invasion
cells.
Peptide
11382
is
target
neutralizing
antibody
72A1;
induce
interleukin-6
production;
11435
binds
to
integrin
αvβ6,
triggers
a
cytokine
storm.
HPV
L1
protein,
major
component
capsid,
18283
18294
identified
as
epithelial
cell-binding
located
on
surface.
Parts
recognized
by
anti-HPV
antibodies.
These
two
along
18301,
potential
biomarkers
infection
because
they
antibodies
elicited
during
natural
infection,
suitable
targets
serological
detection.
envelope
E1
E2
HCV,
five
hepatocyte-
CD81-positive
identified.
The
contain
linear
B-cell
epitopes
antibodies,
used
develop
tests
determining
HCV
infection.
approaches
can
lead
innovative
prevention,
diagnosis,
treatment
diseases.
Additionally,
their
be
modulate
response
generate
tools
cancer
theragnostic.
Язык: Английский
EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma
Vaccines,
Год журнала:
2025,
Номер
13(5), С. 478 - 478
Опубликована: Апрель 29, 2025
Epstein-Barr
virus
(EBV),
a
ubiquitous
human
herpesvirus,
has
been
robustly
linked
to
the
pathogenesis
of
nasopharyngeal
carcinoma
(NPC).
The
mechanism
EBV-induced
NPC
involves
complex
interactions
between
viral
proteins
and
host
cell
pathways.
This
review
aims
comprehensively
outline
latest
advances
in
targeted
EBV
vaccines
for
prophylaxis
treatment.
explores
intricate
molecular
mechanisms
by
which
contributes
pathogenesis,
highlighting
latency,
genetic
epigenetic
alterations,
immune
evasion
strategies.
It
emphasizes
pivotal
role
key
proteins,
including
EBNA1,
LMP1,
LMP2A,
carcinogenesis.
Subsequently,
discussion
shifts
towards
development
vaccines,
preventive
aimed
at
preventing
primary
infection
therapeutic
treating
diagnosed
EBV-related
NPC.
underscores
challenges
future
directions
field,
stressing
importance
developing
innovative
vaccine
strategies
combination
therapies
improve
efficacy.
synthesizes
current
insights
into
EBV-targeted
potential
use
mRNA
Язык: Английский
A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update
Pharmaceuticals,
Год журнала:
2024,
Номер
17(9), С. 1121 - 1121
Опубликована: Авг. 24, 2024
Researchers
have
performed
numerous
studies
on
immunotherapy
because
of
the
high
death
rate
associated
with
gastric
cancer
(GC).
GC
research
has
made
tremendous
progress,
and
we
wanted
to
provide
an
update
this
topic.
On
basis
update,
suggest
performing
a
new
medical
evaluation
before
initiating
in
patients
increase
success
immunotherapies.
We
propose
that
start
immunotherapy,
they
should
be
evaluated
given
score
one
two
points
for
following
factors:
immunopathological
features,
molecular
genomic
potential
consequences
bacterial
pathogens,
immunotherapeutic
resistance
hyperprogressive
illness,
use
biomarkers
gauge
their
prognosis
responses
optimize
surgery.
The
proposed
scoring
system
could
also
help
diagnosis
GC.
With
all
advances
genetics,
immunology,
microbiology,
improved,
not
changed.
Currently,
diagnosed
undergo
surgical
resection
as
only
permanent
solution.
Patients
who
meet
maximum
from
presented
proposal
eligible
immediately
after
immunotherapy.
Therefore,
first-line
option
clinicians.
Язык: Английский